Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. LFMD
stocks logo

LFMD

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
48.57M
-24.41%
-0.060
+200%
50.07M
-23.78%
-0.112
-1216.7%
53.73M
-13.64%
-0.105
+75%
Estimates Revision
The market is revising Downward the revenue expectations for LifeMD, Inc. (LFMD) for FY2025, with the revenue forecasts being adjusted by -6.26% over the past three months. During the same period, the stock price has changed by -38.45%.
Revenue Estimates for FY2025
Revise Downward
down Image
-6.26%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-38.45%
In Past 3 Month
Wall Street analysts forecast LFMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LFMD is 9.67 USD with a low forecast of 6.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast LFMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LFMD is 9.67 USD with a low forecast of 6.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 3.730
sliders
Low
6.00
Averages
9.67
High
15.00
Current: 3.730
sliders
Low
6.00
Averages
9.67
High
15.00
H.C. Wainwright
Yi Chen
Buy
downgrade
$13 -> $9
2025-11-19
Reason
H.C. Wainwright
Yi Chen
Price Target
$13 -> $9
2025-11-19
downgrade
Buy
Reason
H.C. Wainwright analyst Yi Chen lowered the firm's price target on LifeMD to $9 from $13 and keeps a Buy rating on the shares following a top- and bottom-line miss in Q3. LifeMD, which is now a pure-play telehealth and pharmacy platform after the company divested its majority ownership in WorkSimpli, updated its 2025 total revenue guidance and the firm adjusted its projections accordingly, the analyst noted.
KeyBanc
Scott Schoenhaus
Overweight
downgrade
$12 -> $8
2025-11-19
Reason
KeyBanc
Scott Schoenhaus
Price Target
$12 -> $8
2025-11-19
downgrade
Overweight
Reason
KeyBanc analyst Scott Schoenhaus lowered the firm's price target on LifeMD (LFMD) to $8 from $12 and keeps an Overweight rating on the shares. The firm notes LifeMD is being impacted by low-cost compounders despite the FDA outlawing the practice earlier this year. However, KeyBanc expects cash prices for brand-name GLP-1s to continue to come down as well as stricter enforcement against compounders in FY26, which should benefit LifeMD due to its partnerships with Eli Lilly (LLY) and Novo (NVO). The firm also expects the launch of oral Wegovy in early FY26 to drive higher weight management subscribers.
B. Riley
Buy
downgrade
$12 -> $10
2025-11-18
Reason
B. Riley
Price Target
$12 -> $10
2025-11-18
downgrade
Buy
Reason
B. Riley lowered the firm's price target on LifeMD to $10 from $12 and keeps a Buy rating on the shares. LifeMD reported a Q3 top- and bottom-line miss with lowered guidance for the telehealth business, largely due to increased competition from compounded GLP-1 providers, the analyst tells investors in a research note. LifeMD is well-positioned entering 2026 with multiple drivers of growth, including oral semaglutide launch expected in January, Medicare obesity coverage, 503(a) pharmacy expansion, and ramping women's health and behavioral health offerings.
Lake Street
Ryan Meyers
Buy
downgrade
$14 -> $8
2025-11-18
Reason
Lake Street
Ryan Meyers
Price Target
$14 -> $8
2025-11-18
downgrade
Buy
Reason
Lake Street analyst Ryan Meyers lowered the firm's price target on LifeMD to $8 from $14 and keeps a Buy rating on the shares. Q3 results reflect "operational progress," but a headwind from competitive pressures in the weight management business ultimately led to revised guidance for the standalone Telehealth business, the analyst tells investors. The firm is lowering its target based on revised estimates and a lower multiple.
BTIG
Buy
downgrade
$18 -> $10
2025-11-18
Reason
BTIG
Price Target
$18 -> $10
2025-11-18
downgrade
Buy
Reason
BTIG lowered the firm's price target on LifeMD to $10 from $18 and keeps a Buy rating on the shares. LifeMD's results reflected pressure on weight management from competitors who are offering lower-cost and potentially lower-quality compounded GLP-1 products, that are under-pricing more established platforms like LifeMD who more closely follow regulatory and quality protocols, the analyst tells investors in a research note. BTIG believes the headwinds and revenue lumpiness are temporary, and growth should reaccelerate in 2026.
H.C. Wainwright
Buy
downgrade
$14 -> $13
2025-08-07
Reason
H.C. Wainwright
Price Target
$14 -> $13
2025-08-07
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on LifeMD to $13 from $14 and keeps a Buy rating on the shares. The company reported a Q2 miss and reduced its outlook, the analyst tells investors in a research note.
See All Ratings

Valuation Metrics

The current forward P/E ratio for LifeMD Inc (LFMD.O) is -10.46, compared to its 5-year average forward P/E of -18.66. For a more detailed relative valuation and DCF analysis to assess LifeMD Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-18.66
Current PE
-10.46
Overvalued PE
39.82
Undervalued PE
-77.13

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
6.40
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
17.17
Undervalued EV/EBITDA
-4.37

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1.31
Current PS
0.00
Overvalued PS
2.35
Undervalued PS
0.27
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

LFMD News & Events

Events Timeline

(ET)
2025-11-17
16:10:41
LifeMD Revises FY25 Revenue Forecast Downward to $192M-$193M from Previous Estimate of $250M-$255M
select
2025-11-17
16:08:44
LifeMD Reports Q4 Revenue Between $45M and $46M, Below Consensus Estimate of $63.07M
select
2025-11-17
16:07:37
LifeMD Announces Q3 Earnings Per Share of 10 Cents, Exceeding Consensus Estimate of 5 Cents
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-22Benzinga
Benzinga Market Update: Nvidia, Webull, Netflix, and Tech Stocks Experience Largest Sell-Off Since April

  • Nvidia's Strong Performance: Nvidia Corp. reported a record $57 billion in revenue and earnings of $1.30 per share, surpassing estimates, but the tech sector faced a significant sell-off, losing over $800 billion in market value amid valuation concerns.

  • Market Reactions: Following Nvidia's results, stocks in high-performance computing and AI sectors surged, while companies like Netflix and Home Depot experienced declines due to strategic concerns and a weak housing market, respectively.

  • Investor Sentiment: The tech sell-off has raised worries about the sustainability of the "AI bubble," with investors now focusing on upcoming inflation and labor data to assess potential Federal Reserve rate cuts.

  • Benzinga's Coverage: Benzinga highlighted both bullish and bearish stock movements, including notable earnings beats from Webull and Oddity Tech, contrasted with disappointing results from LifeMD and Netflix.

[object Object]
Preview
6.0
11-20Benzinga
Eli Lilly Set for Over 12% Surge? Check Out 10 Leading Analyst Predictions for Wednesday

  • Analyst Downgrades: Morgan Stanley lowered Harley-Davidson's price target from $25 to $21 while maintaining an Underweight rating, and Citigroup cut Westlake Corp's target from $88 to $75 but kept a Buy rating.

  • Analyst Upgrades: B of A Securities raised Baidu's price target from $100 to $151 with a Buy rating, and Truist Securities increased Eli Lilly's target from $1,038 to $1,182, also maintaining a Buy rating.

  • Mixed Ratings: Oppenheimer reduced Varex Imaging's price target from $23 to $18 while keeping an Outperform rating, and Evercore ISI Group cut Home Depot's target from $450 to $425 but maintained an Outperform rating.

  • Other Notable Changes: HC Wainwright & Co. lowered LifeMD's target from $13 to $9 while keeping a Buy rating, and UBS cut Aecom's target from $153 to $148 while maintaining a Buy rating.

[object Object]
Preview
6.0
11-20Benzinga
HC Wainwright & Co. Reaffirms Buy Rating for LifeMD, Adjusts Price Target to $9

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.

  • Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters, enhancing their trading strategies.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and experiences.

  • Market Winning Tools: The platform is designed to provide traders with the tools and information necessary to succeed in their trading endeavors.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is LifeMD Inc (LFMD) stock price today?

The current price of LFMD is 3.73 USD — it has increased 0.27 % in the last trading day.

arrow icon

What is LifeMD Inc (LFMD)'s business?

LifeMD, Inc. is a provider of virtual healthcare services and pharmacy services. The Company offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across 200 conditions, including primary care, men’s and women’s health, mental health, and weight management. Its Telehealth platform is end-to-end virtual healthcare directly to consumers and through select enterprise partnerships. In addition, the Company is focused on developing its Rex MD product portfolio, which is primarily focused on asynchronous men’s healthcare, e-pharmacy solutions, and men’s hormonal health. The Company owns a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a state-of-the-art affiliated compounding pharmacy, and a United States based patient care center.

arrow icon

What is the price predicton of LFMD Stock?

Wall Street analysts forecast LFMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LFMD is 9.67 USD with a low forecast of 6.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is LifeMD Inc (LFMD)'s revenue for the last quarter?

LifeMD Inc revenue for the last quarter amounts to 60.17M USD, increased 12.95 % YoY.

arrow icon

What is LifeMD Inc (LFMD)'s earnings per share (EPS) for the last quarter?

LifeMD Inc. EPS for the last quarter amounts to -0.10 USD, decreased -23.08 % YoY.

arrow icon

What changes have occurred in the market's expectations for LifeMD Inc (LFMD)'s fundamentals?

The market is revising Downward the revenue expectations for LifeMD, Inc. (LFMD) for FY2025, with the revenue forecasts being adjusted by -6.26% over the past three months. During the same period, the stock price has changed by -38.45%.
arrow icon

How many employees does LifeMD Inc (LFMD). have?

LifeMD Inc (LFMD) has 304 emplpoyees as of December 05 2025.

arrow icon

What is LifeMD Inc (LFMD) market cap?

Today LFMD has the market capitalization of 178.97M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free